In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB – Research Report), with a price target of $34.00. The company’s shares opened today at $11.29.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Madrigal Pharmaceuticals. According to TipRanks, Wolleben has an average return of -3.2% and a 45.76% success rate on recommended stocks.
Currently, the analyst consensus on Rallybio is a Moderate Buy with an average price target of $34.00.
The company has a one-year high of $21.00 and a one-year low of $5.90. Currently, Rallybio has an average volume of 87.09K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLYB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Read More on RLYB:
- TSS, INC. TO REPORT SECOND QUARTER 2022 RESULTS ON MONDAY, AUGUST 15th, 2022
- Nvidia (NVDA) Gets a Buy from Needham
- Tesla Is Miles Ahead of the Competition, Says Analyst
- Superior Industries International (SUP) Receives a Rating Update from a Top Analyst
- HealthEquity Recognized as Top Workplace in Arizona